| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
0.086 μM (IGF-1R)[1]
Chimaphilin targets the insulin-like growth factor 1 receptor (IGF-1R). By inhibiting IGF-1R with an IC50 of 0.086 μM, it blocks the signaling pathways that promote tumor cell proliferation and survival. Its other biological activities, including antimicrobial and antifungal properties, suggest it may interact with multiple cellular targets. |
|---|---|
| ln Vitro |
In vitro, Chimaphilin has been shown to be an IGF-1R inhibitor with an IC50 of 0.086 μM. It also exhibits antifungal, antioxidant, and anticancer activities. Its activity is typically assessed using cell-based assays that measure IGF-1R phosphorylation and downstream signaling in IGF-responsive cancer cell lines. These studies confirm its potential as a therapeutic agent.
|
| ln Vivo |
In vivo activity of Chimaphilin is not extensively documented. As a naturally occurring compound, its efficacy is likely evaluated in animal models of cancer or other diseases. Its antioxidant and anti-inflammatory properties suggest potential benefits in various disease models. Further studies are needed to fully characterize its in vivo effects.
|
| Enzyme Assay |
Cell-free assays for Chimaphilin typically involve measuring its inhibitory activity against IGF-1R using biochemical kinase assays. The IC50 value of 0.086 μM is determined by measuring the phosphorylation of a substrate in the presence of varying concentrations of the inhibitor. These assays are used to characterize the compound's potency.
|
| Cell Assay |
In vitro cellular assays are conducted to evaluate the functional activity of Chimaphilin. Cancer cell lines are treated with the compound. Cell viability and proliferation are measured to assess the compound's anti-proliferative effects. IGF-1R phosphorylation is also measured to confirm inhibition of the target kinase.
|
| Animal Protocol |
In vivo animal experiments are not typically performed with Chimaphilin as a primary research focus, given its status as a natural product. However, its effects could be studied in animal models of cancer or inflammation. Such studies would involve administering the compound and monitoring disease progression or relevant biomarkers.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Chimaphilin are not well-characterized. As a natural naphthoquinone, its absorption, distribution, metabolism, and excretion would be influenced by its chemical properties. Its molecular weight is 186.21. Further studies are needed to determine its bioavailability and half-life.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Chimaphilin is not extensively documented. As a naturally occurring compound, it is generally considered to have low toxicity, but standard safety precautions should be taken when handling it. Its use is restricted to research purposes and it is not intended for human consumption.
|
| References |
|
| Additional Infomation |
Chimaphylin is a 1,4-naphthoquinone compound. It has been reported to exist in Pyrrosia lingua, Pyrrosia kauri, and other organisms with relevant data.
Chimaphilin is a naturally occurring naphthoquinone with IGF-1R inhibitory activity (IC50 = 0.086 μM). It exhibits a range of biological activities, including antimicrobial, antifungal, antioxidant, and anticancer properties. It is isolated from plants of the genus Chimaphila and is used in research to study its potential therapeutic applications. |
| Molecular Formula |
C12H10O2
|
|---|---|
| Molecular Weight |
186.2066
|
| Exact Mass |
186.068
|
| CAS # |
482-70-2
|
| PubChem CID |
101211
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.187g/cm3
|
| Boiling Point |
346.8ºC at 760mmHg
|
| Flash Point |
130.1ºC
|
| Vapour Pressure |
5.6E-05mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
2.32
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
14
|
| Complexity |
314
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1C=CC2C(C=C(C(=O)C=2C=1)C)=O
|
| InChi Key |
YZACZIYTZCJVSN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10O2/c1-7-3-4-9-10(5-7)12(14)8(2)6-11(9)13/h3-6H,1-2H3
|
| Chemical Name |
2,7-dimethylnaphthalene-1,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3703 mL | 26.8514 mL | 53.7028 mL | |
| 5 mM | 1.0741 mL | 5.3703 mL | 10.7406 mL | |
| 10 mM | 0.5370 mL | 2.6851 mL | 5.3703 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
